NMN 2025-2026 Clinical Trials Update: What the New Research Shows
June 4, 2026 · Nadovia Research Team
Research Update · Updated June 2026
The NMN human evidence base has changed significantly since the landmark Yoshino et al. trial in 2021. By June 2026, multiple independent research groups have published findings on NMN across different populations, longer timeframes, and a broader range of outcomes. For Australian buyers making decisions based on the science, this update matters.
The 2024-2026 Research: What's New
Longer Safety Duration
One of the most significant developments: published human trials now extend to 24 weeks (6 months). The earlier evidence base was primarily 8–12 weeks. The 24-week data continues to show no significant adverse effects at doses up to 600mg daily — strengthening the long-term safety picture and providing the first published data past the 12-week window.
Physical Performance — More Evidence
Multiple trials published in 2024-2025 have expanded the physical performance evidence beyond the 2021 running trial. New findings include improved grip strength in adults over 60, improved physical function scores in community-dwelling older adults, and improved VO2-related markers in a different running population. The physical performance evidence is now the most robust area of the clinical literature.
Sleep Quality — Additional Confirmation
The 2022 Igarashi sleep findings have been reinforced by additional trial data published in 2024-2025 confirming improvements in sleep architecture markers. The sleep quality benefit — deep sleep ratio improvement and reduced nocturnal awakenings — is now among the more consistently replicated subjective outcomes in the NMN literature.
Metabolic and Cardiovascular Markers
New 2024 data from a trial in adults with metabolic syndrome showed NMN supplementation reduced fasting glucose, improved insulin sensitivity, and modestly reduced blood pressure compared to placebo over 16 weeks. This extends the 2021 Yoshino insulin sensitivity finding to a broader population and longer timeframe.
The Australian TGA Approval — December 2025
Australia's TGA became the first regulatory body to formally approve NMN as a therapeutic ingredient in December 2025. This approval was based on a safety and quality evidence review. It does not constitute TGA endorsement of specific health claims about NMN — but it does signal that Australia's pharmaceutical-grade regulatory standard has been applied and found NMN to be an acceptable therapeutic ingredient.
What Remains Uncertain
Honest assessment of where the evidence is still limited:
- Longevity outcomes in humans: No human trial has measured NMN's effects on lifespan, age-related disease prevention, or biological age markers (telomere length, epigenetic clocks) in a controlled long-term trial. These remain animal model findings.
- Cognitive endpoints: While improved subjective cognitive function and reduced fatigue are documented, specific cognitive test improvements remain less consistent across trials than energy and physical performance outcomes.
- Dose optimisation: Comparative dose trials (500mg vs 1000mg head-to-head in the same population) remain limited. The dose-response relationship above 500mg is not well-characterised in humans.
- Sex differences: The Yoshino trial was specific to postmenopausal women. Sex-stratified analysis in other trials remains limited — many trials have mixed populations without adequate reporting of sex-specific effects.
What This Means for Australian Buyers in 2026
The 2026 evidence picture: NMN reliably raises NAD+ in humans — this is now beyond debate. Physical performance and sleep improvements are the most consistently documented downstream benefits. Metabolic improvements (insulin sensitivity, glucose) have meaningful multi-trial support. Long-term safety beyond 12 weeks now has 24-week published data with no significant adverse effects.
This is a stronger evidence base than existed when most people first heard about NMN in 2021-2022. The molecule has moved from promising-but-limited-human-data to a supplement category with a genuine and growing body of controlled human evidence.
The caveat remains: NMN is not a proven longevity intervention in humans. It is a supplement with strong mechanistic rationale, good human evidence for specific outcomes, and an expanding clinical base. That is the honest 2026 position.
FAQ
What do the 2025-2026 NMN trials show?
Strengthened evidence in: 24-week safety data (no significant adverse effects), physical performance (multiple trials with multiple populations), sleep quality (additional confirmation), and metabolic markers (insulin sensitivity, glucose in metabolic syndrome adults). The evidence base is stronger than in 2021.
Is the NMN evidence stronger in 2026?",
Yes. Multiple independent research groups have confirmed NAD+ elevation and documented downstream benefits across physical performance, sleep, and metabolic function. Long-term safety data now extends to 24 weeks. The human evidence base has genuinely strengthened since the 2021 landmark trials.
Has the TGA approval changed the NMN story for Australians?",
The December 2025 TGA approval signals regulatory confidence in NMN's safety profile and creates a quality accountability framework for Australian brands. It does not constitute TGA endorsement of health claims. But it does make Australia the first country with NMN-specific therapeutic regulation — a meaningful quality signal.
The evidence has strengthened. The formula hasn't needed to change.
Nadovia's Longevity Complex — built on the research from day one. Free AU shipping over $75.
View Longevity Complex →References: Yoshino M et al., Cell Metabolism (2021); Igarashi M et al., NPJ Aging (2022); 2024-2025 extended safety trials (multiple sources); tga.gov.au NMN approval December 2025. Not medical advice.